News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Senthil Damodaran

Articles by Senthil Damodaran

TPS 83 ELAINE 3: Open-Label, Randomized, Multicenter, Phase 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating Locally Advanced or Metastatic, ER+/HER2–, Breast Cancer With an ESR1 Mutation

ByDavid J. Portman,Matthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Guiseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Sarah Sammons, MD,Sherry Shen, MD,Christ Twelves,Paul V. Plourde,Senthil Damodaran

April 27th 2025

16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation

Futibatinib/Fulvestrant AEs Remains Consistent in Advanced FGFR+ Breast Cancer

BySenthil Damodaran,Rina Lokaj

January 2nd 2024

Potential Combination Regimens With Fulvestrant in HR+/HER2− Breast Cancer

BySenthil Damodaran,Rina Lokaj

December 30th 2023

Final Results Show PFS Benefit With Futibatinib for HR+ HER2– Breast Cancer

ByRina Lokaj,Senthil Damodaran

December 29th 2023

9 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/ Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

ByAditya Bardia, MD, MPH, FASCO,Ian E. Krop,Dejan Juric,Takahiro Kogawa,Erika P. Hamilton, MD,Alexander Spira, MD, PhD, FACP,Toru Mukohara,Takuya Tsunoda,Senthil Damodaran,Funda Meric-Bernstam, MD

April 28th 2023

37 Open-Label, Phase 2, Multicenter Study of Lasofoxifene (LAS) Combined With Abemaciclib (Abema) for Treating Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation After Progression on Prior Therapies

ByDavid J. Portman,Senthil Damodaran,Paul V. Plourde,Halle C. F. Moore, MD,Ian C. Anderson

April 27th 2023

Latest Updated Articles

Potential Combination Regimens With Fulvestrant in HR+/HER2− Breast Cancer
Published: December 30th 2023 | Updated:

Trending on CancerNetwork

Evaluating the Viability of Antibody Drug Conjugates for Glioblastoma

Could Scorpion Venom Component Play a Role in Glioblastoma Management?

FDA Approves Abbreviated NDA for Dasatinib Tablets in Leukemia Indications

FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma

What Were The Most Impactful GU Oncology Data From ESMO 2025?

© 2025 MJH Life Sciences^®

All rights reserved.